SCHEMBL29623746

SCHEMBL29623746

O=C(C=CCN1CCCOCC1)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1

nearest known ligand 0.92

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 20/20 0.92
ERBB2 P04626 9/20 0.81
ERBB4 Q15303 3/20 0.75
GAK O14976 2/20 0.75
ABL1 P00519 2/20 0.75
LCK P06239 2/20 0.75
MET P08581 2/20 0.75
PHKG2 P15735 2/20 0.75
BLK P51451 2/20 0.75
IRAK1 P51617 2/20 0.75
DYRK1A Q13627 2/20 0.75
HIPK4 Q8NE63 2/20 0.75
EPHA6 Q9UF33 2/20 0.75
CIT O14578 1/20 0.75
EPHB6 O15197 1/20 0.75
RIPK2 O43353 1/20 0.75
STK10 O94804 1/20 0.75
LYN P07948 1/20 0.75
RET P07949 1/20 0.75
CHRM2 P08172 1/20 0.75

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10128118 1.00 EGFR (0.92) EGFRERBB2ERBB4GAKABL1
SCHEMBL14427867 1.00 EGFR (0.92) EGFRERBB2ERBB4GAKABL1
SCHEMBL14066601 0.97 EGFR (0.87) EGFRERBB2ERBB4GAKABL1
SCHEMBL1191715 0.97 EGFR (0.91) EGFRERBB2ERBB4GAKABL1
SCHEMBL1191713 0.97 EGFR (0.91) EGFRERBB2ERBB4GAKABL1
SCHEMBL1191712 0.97 EGFR (0.91) EGFRERBB2ERBB4GAKABL1
SCHEMBL14066620 0.97 EGFR (0.85) EGFRERBB2ERBB4GAKABL1
SCHEMBL14149370 0.96 EGFR (0.96) EGFRERBB2ERBB4GAKABL1
SCHEMBL15772053 0.96 EGFR (0.96) EGFRERBB2ERBB4GAKABL1
SCHEMBL18595838 0.96 EGFR (1.00) EGFRERBB2ERBB4GAKABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119403567-A AMHR2-ED cancer vaccine formulation 克利夫兰诊所基金会 2025-02-07 CN disclosed
US-20230312658-A1 EPITOPE FOCUSING BY VARIABLE EFFECTIVE ANTIGEN SURFACE CONCENTRATION CENTIVAX, INC. 2023-10-05 US disclosed
EP-4218806-A1 COMPOSITIONS AND KITS FOR ELICITING AN IMMUNE RESPONSE Duke University (US) 2023-08-02 EP disclosed
US-20220387582-A1 Compositions, Methods and Kits for Eliciting an Immune Response DUKE UNIVERSITY (US) 2022-12-08 US disclosed
EP-3766517-B1 COMPOSITIONS, METHODS, AND KITS FOR ELICITING AN IMMUNE RESPONSE UNIV DUKE (US) 2022-11-02 EP disclosed
CN-110713489-B Heteroaryl SYK inhibitors 勃林格殷格翰国际有限公司 2022-05-31 CN disclosed
CN-110183440-B Heteroaryl SYK inhibitors 勃林格殷格翰国际有限公司 2022-04-22 CN disclosed